Aidi injection / GastroP Cancer Research Results

Aidi, Aidi injection: Click to Expand ⟱

Features:

Aidi Injection - Chinese herbal anticancer injection

Type: Multi-component traditional Chinese medicine injectable formulation

Components: Mylabris phalerata / Cantharis (including cantharidin-related constituents), Astragalus membranaceus, Panax ginseng, and Acanthopanax senticosus (Eleutherococcus senticosus).

Function: Multi-component anticancer formulation used primarily as an adjunct to chemotherapy and radiotherapy. Reported actions include inhibition of tumor-cell proliferation, induction of apoptosis, modulation of immune responses, inhibition of invasion and metastasis, and reduction of chemotherapy-associated hematologic, gastrointestinal, hepatic, and renal toxicity.

Cancer: ↓ Tumor growth/progression. Clinical studies and meta-analyses, primarily from China, report improved objective response rate, disease control rate, and quality of life when Aidi injection is combined with conventional chemotherapy in several cancers. Evidence quality ranges from moderate to very low, and substantial geographic, publication, and methodological bias remain concerns.

GastroP, GastroProtective: Click to Expand ⟱

Source:

Type:

GastroProtective refers to an effect that helps protect the gastrointestinal mucosa, especially the stomach, from injury caused by acid, NSAIDs, alcohol, infection, oxidative stress, or inflammation. Gastroprotective actions may involve enhancement of mucus and bicarbonate defenses, preservation of mucosal blood flow, reduction of oxidative damage, suppression of inflammatory signaling, and support of epithelial repair. In cancer and IBD-related contexts, gastroprotective or broader mucosal-protective effects may be relevant when a compound reduces treatment-related GI injury, limits inflammatory mucosal damage, or helps preserve barrier integrity, although this term is supportive and protective rather than a direct anticancer mechanism.

Scientific Papers found: Click to Expand⟱

7290-

PacT,

Aidi,

Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines

Dose↝, QoL↑, hepatoP↑, GastroP↑, chemoP↑, Dose↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Barriers & Transport(tgid=15) ⓘ

GastroP↑, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 2,

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1, hepatoP↑, 1, QoL↑, 1,
Total Targets: 5

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: GastroP, GastroProtective

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells